Observational studySurgery today2015
Effects of tolvaptan in the early postoperative stage after heart valve surgery: results of the STAR (Study of Tolvaptan for fluid retention AfteR valve surgery) trial.
Observational study in Surgery today, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- The effect of tolvaptan on renal excretion of electrolytes and urea nitrogen in patients undergoing coronary artery bypass surgery.BMC cardiovascular disorders · 2016Trial
- Feasibility and safety of intravenous tolvaptan administration immediately upon ICU admission after cardiac surgery with cardiopulmonary bypass.Surgery today · 2026Article
- Safety and efficacy of tolvaptan sodium phosphate in patients undergoing open-heart surgery.Surgery today · 2026Article
- Efficacy of tolvaptan in postoperative volume therapy for acute Stanford type A aortic dissection.BMC cardiovascular disorders · 2023Article
- Effects of Low-Dose Tolvaptan for Fluid Management After Cardiovascular Surgery.Circulation reports · 2022Article
- The Efficacy and Renal Protective Effect of Tolvaptan in Chronic Kidney Disease Patients after Open-Heart Surgery.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2021Article
- Efficacy of tolvaptan for fluid management after cardiovascular surgery: A systematic review and meta-analysis of randomized control trials.Experimental and therapeutic medicine · 2020Article
- Tolvaptan can limit postoperative paroxysmal atrial fibrillation occurrence after open-heart surgery.Surgery today · 2020Article
- Perioperative urinary excretion of aquaporin-2 dependent upon vasopressin in cardiac surgery.Heart and vessels · 2020Observational
- Hemodynamic and Hormonal Effects of Tolvaptan for Heart Failure.Internal medicine (Tokyo, Japan) · 2019Review
- Safety and effectiveness of tolvaptan for fluid management after pediatric cardiovascular surgery.General thoracic and cardiovascular surgery · 2017Article
- Predictive factors for responders to tolvaptan in fluid management after cardiovascular surgery.General thoracic and cardiovascular surgery · 2017Article
- Efficacy of vaptans for correction of postoperative hyponatremia: A comparison between single intravenous bolus conivaptan vs oral tolvaptan.Journal of anaesthesiology, clinical pharmacologyArticle
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to assess the efficacy of tolvaptan, a vasopressin V2 receptor antagonist, for the management of postoperative surgical fluid retention after heart valve surgery.
methodsThis was a prospective observational study of 64 patients with heart valve disease who underwent valve surgery between 2013 and 2014. Those in the tolvaptan group received tolvaptan in addition to conventional diuretic therapy. The results were compared to the results of 55 patients who underwent heart valve surgery between 2007 and 2010 and received conventional postoperative diuretics alone.
resultsThe time to return to the preoperative BW was significantly shorter in the patients who received tolvaptan (6.1 ± 3.8 vs. 8.7 ± 6.7 days, p < 0.05), while the level of sodium was significantly decreased in the patients who received conventional diuretics. The degree of increase in the creatinine level tended to be smaller in the tolvaptan group. The response to tolvaptan was related to the postoperative degree of BW increase and the preoperative creatinine level.
conclusionsTolvaptan was effective in treating fluid retention during the early postoperative stage in cardiac surgery patients, without increased renal failure or abnormal electrolyte levels. This new type of diuretic therapy may be a suitable option for postoperative fluid management in patients undergoing cardiac surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.